Patents by Inventor Emily Manktelow

Emily Manktelow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR agonist-enhanced in vitro assay of cell mediated immune responsiveness
    Patent number: 11841367
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: December 12, 2023
    Assignee: Cellestis Limited
    Inventors: Jeff Boyle, Emily Manktelow
  • TLR AGONIST-ENHANCED IN VITRO ASSAY OF CELL MEDIATED IMMUNE RESPONSIVENESS
    Publication number: 20200271648
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
    Type: Application
    Filed: December 16, 2019
    Publication date: August 27, 2020
    Inventors: Jeff Boyle, Emily Manktelow
  • Diagnostic assay
    Patent number: 10578612
    Abstract: The present disclosure relates generally to the field of immunological-based diagnostic assays. Particularly, a method is contemplated herein for measuring cell-mediated immune response reactivity. The present disclosure further provides a method to reduce incidence of non-specific immune response reactivity in a cell-mediated immune response-based assay, comprising contacting a sample with a basic peptide structure capable of binding to lipopolysaccharides, such as polymyxin B or a sushi peptide.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: March 3, 2020
    Assignee: Cellestis International Pty Ltd.
    Inventors: Anthony J. Radford, Emily Manktelow, Jeff Boyle, Jenny Louise Howard
  • TLR agonist-enhanced in vitro assay of cell mediated immune responsiveness
    Patent number: 10551380
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 4, 2020
    Assignee: Cellestis Limited
    Inventors: Jeff Boyle, Emily Manktelow
  • ASSAY OF CELL MEDIATED IMMUNE RESPONSIVENESS
    Publication number: 20140154712
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches determination of the state, progression and/or severity of disease conditions based on a subject's cell-mediated immunoresponsiveness. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 5, 2014
    Applicant: CELLESTIS LIMITED
    Inventors: Jeff Boyle, Emily Manktelow
  • DIAGNOSTIC ASSAY
    Publication number: 20130289139
    Abstract: The present disclosure relates generally to the field of immunological-based diagnostic assays. Particularly, a method is contemplated herein for measuring cell-mediated immune response reactivity. The present disclosure further provides a method to reduce incidence of non-specific immune response reactivity in a cell-mediated immune response-based assay, comprising contacting a sample with a basic peptide structure capable of binding to lipopolysaccharides, such as polymyxin B or a sushi peptide.
    Type: Application
    Filed: May 23, 2011
    Publication date: October 31, 2013
    Applicant: CELLESTIS INTERNATIONAL PTY LTD.
    Inventors: Anthony J. Radford, Emily Manktelow, Jeff Boyle, Jenny Louise Howard